CD274 and neoplasm: The predictive value of tumor PD-L1 expression and tumor mutational burden (TMB) as auxiliary diagnostic biomarkers for other tumor types remained doubtful in cases of ccRCC [12], since many studies have shown that this did not correlate with the response of patients with ccRCC to immunotherapy [13].